Clin2
NCT06136195Possibly a fitRecruiting

Mavoglurant for alcohol craving in heavy drinkers

Alcohol ConsumptionHeavy DrinkerAlcohol Use Disorder (AUD)

Part of Mental health clinical trials.

This trial tests whether a medication called mavoglurant can reduce alcohol cravings and drinking in people who are heavy drinkers with alcohol use disorder and are not looking for treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
63 people
Ages
21 years to 50 years
Study type
Interventional

Who can take part

  • You are between 21 and 50 years old
  • You are a heavy drinker (men: 30-70 drinks/week, women: 20-65 drinks/week)
  • You have been diagnosed with moderate or severe alcohol use disorder
  • You are not currently seeking treatment for alcohol and haven't been in treatment in the last 6 months
  • You do not have a current substance use disorder other than tobacco or mild cannabis
  • You are generally healthy, especially your liver, and are not pregnant or nursing

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05491551Recruiting
Alcohol training program to help you cut back or quit

This study tests a structured training program for young adults who’ve been drinking heavily, to help them reduce drinking or quit. You’ll be asked to complete daily short check-ins and follow study instructions, and you may be randomly assigned to different parts of the program.

Berkeley, California
NCT05408247Recruiting· Phase 4
N-acetylcysteine to help people cut back on alcohol

This trial tests whether N-acetylcysteine (a supplement-like medicine) can help people with alcohol use disorder reduce or stop drinking. You may be randomly assigned to receive N-acetylcysteine or a comparison treatment, and you’ll complete interviews during the study.

Sydney, New South Wales
NCT05203965Recruiting· Early Phase 1
Brain imaging study testing mavoglurant in alcohol risk

This early-stage study uses brain scans to understand how brain signaling tied to alcohol vulnerability works, and it tests mavoglurant, a medicine that blocks a brain receptor. Results may help researchers learn why some people are more vulnerable to alcohol problems.

Hartford, Connecticut
NCT07029529Recruiting· Phase 2
Apremilast for alcohol use disorder

This study tests whether a drug called apremilast can help people who drink heavily reduce their alcohol use. You will take the medication daily for several weeks and attend study visits to track your progress.

New Haven, Connecticut
NCT06900998Not yet recruiting· Phase 2
Nimodipine study for heavy drinkers

This trial tests if a blood pressure medication called nimodipine can help reduce alcohol drinking in people with moderate to severe alcohol use disorder. You'll take the medication or a placebo and participate in drinking sessions to see how it affects your alcohol intake.

New Haven, Connecticut
NCT04084860Recruiting· Phase 2
Brief medicine trial to help reduce heavy alcohol drinking

This Phase 2 study tests a brief medication approach meant to reduce “problem drinking.” It may help people cut back or stop alcohol use by adjusting brain signaling related to drinking cravings and urges.

New York, New York

Hear when a new Alcohol Consumption trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.